Pretreatment characteristics of patients
| Reference | n | Mean/median age (range) |
Mediastinoscopy (%) |
Staged with CT (%) |
Declined surgery (n) |
Unfit for surgery (n) |
| Stage I (T1–2N0) | ||||||
| Haffty (1988)8 | 43 | 64 (51–83) | 4 | 9 | 6 | 37 |
| Noordijk (1988)9 1-a | 50 | |||||
| Sandler (1990)10 | 77 | 72 (44–80+) | 16 | 13 | 64 | |
| Ono (1991)11 | 38 | Not stated | 24 | 4 | 34 | |
| Kaskowitz (1993)12 | 53 | 73 (44–86) | 8 | All | 10 | 43 |
| Slotman (1994)13 1-b | 47 | 75 (57–93) | 55 | 3 | 44 | |
| Gauden (1995)14 | 347 | 70 (34–90) | 87 | Not stated | Not stated | |
| Park (1995)15 | 15 | 66 | Not stated | 2 | 13 | |
| Krol (1996)16 | 108 | 74 (56–88) | 86 | 6 | 102 | |
| Slotman (1996)17 1-b | 31 | 75 (54–85) | All | 2 | 29 | |
| Morita (1997)18b | 149 | 74 (50–89) | All | 26 | 123 | |
| Jeremic (1997)19 | 49 | 63 (51–70) | All | 20 | 29 | |
| Nguyen-Tan (1998)20 1-c | 41 | 69 (53–81) | 36 | All | 4 | 37 |
| Sibley (1998)21 | 141 | 70 (46–95) | 1 | 90 | 2 | 139 |
| Hayakawa (1999)22 1-b | 36 | >70 | 67 | 4 | 32 | |
| Stage IIA (T1–2N1) | ||||||
| Salloum (1990)23 | 61 | 691-d | Some | Not stated | Not stated | |
| Rosenthal (1992)24 | 62 | 68 (46–82) | Some | Not stated | Not stated | |
| Stage I & IIA (T1–2N0–1) | ||||||
| Zhang (1989)25 | 42 | 57 (37–70)1-d | 0 | 12 | 32 | |
| Hayakawa (1992)26 1-a | 64 | |||||
| Schildge (1993)27 | 67 | 66 (not stated) | All earlier patients | Later patients only | Not stated | Not stated |
| Graham (1995)28 | 103 | 67 (43–89) | 3 | 76 | Not stated | Not stated |
| Koukourakis (1995)29 | 64 | 671-d (not stated) | All | Not stated | Not stated | |
| Furuta (1996)30 1-b | 32 | 79 (75–86) | Most | 2 | 30 | |
| Hayakawa (1996)31 | 84 | >70 | Some | 5 | 79 | |
| Hayakawa (1996)32 1-e | 84 | |||||
| King (1996)33 1-a | 11 | |||||
| Saunders (1999),6 Bentzen (2000)7 | 169 | Not stated | All | Not stated | Not stated | |
| Anderson (2000)34 | 36 | 68 (46–82) | All | Not stated | Not stated | |
| Stage I & IIB (T1–3N0) | ||||||
| Talton (1990)35 | 77 | 65 (not stated) | Some | 20 | Not stated | Not stated |
| Dosoretz (1992),36 (1993)37 1-a | 152 | 74 (51–88) | Most | Not stated | Not stated | |
| Dosoretz (1996)38 | 245 | Not stated | 27 | 218 | ||
| Kupelian (1996)39 | 59 | Not stated | All | Not stated | Not stated | |
Data from individual studies have not been included in the table when these data have been included in a subsequent or duplicate series. Data from randomised trial shown in bold.
↵1-a Updated series: patients from Noordijk (1988)9were included in Krol (1996),16 from Hayakawa (1992)26 in Hayakawa (1996),31 from Dosoretz (1992)36 and (1993)37 in Dosoretz (1996),38 and from King (1996)33 in Sibley (1998).21
↵1-b Overlapping series: some patients reported by Hayakawa (1996)31 and Furuta (1996)30 were included in a series with stage I tumours reported by Morita (1997)18 and in a series of peripheral stage I tumours reported by Hayakawa (1999).22 Some patients reported in Hayakawa (1996)31 were included in a subset of elderly patients with stage I/IIA tumours reported by Furuta (1996).30 Slotman (1984)13 and (1987)17 reported patients from overlapping time periods.
↵1-c Published data supplemented by data from authors (Nguyen-Tan, personal communication).
↵1-d Age ranges are those of a larger group which included a proportion of patients with stage III tumours.
↵1-e Duplicate series: Hayakawa (1996)32 reported the same results as Hayakawa (1996).31